Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, First In Human Study of Orally Administered EDP-235 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses, Multiple Ascending Doses, and the Effect of Food on EDP-235 Pharmacokinetics in Healthy Participants

X
Trial Profile

A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, First In Human Study of Orally Administered EDP-235 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses, Multiple Ascending Doses, and the Effect of Food on EDP-235 Pharmacokinetics in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP-235 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man
  • Sponsors Enanta Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2023 According to a Enanta Pharmaceuticals media release, company will have one oral presentation and three poster presentations.
    • 14 Mar 2023 According to a Enanta Pharmaceuticals media release, results of this study are being presented at the 36th International Conference on Antiviral Research (ICAR) Tuesday, March 14 and Wednesday, March 15 at the Centre de Congres de Lyon (Lyon Convention Center) in Lyon, France.
    • 14 Mar 2023 Results presented in an Enanta Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top